Multi-center Study Evaluating OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2014
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Registrational
- Sponsors Cephalon
- 25 Sep 2006 Status change
- 11 Sep 2006 Status change
- 18 Oct 2005 New trial record.